RxDoctor Payments Data

Jimmy Ruiz, MD

Obstetrics & Gynecology · Willow Grove, PANPI 1962408351

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 29.3% of the total. 2025 is the largest year on record at $750, 2.6 times the $288 reported in 2019. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,307in general payments, 2019–2025

Across 157 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$969
  • Daiichi Sankyo Inc.$417
  • Sumitomo Pharma America, Inc.$240
  • Exeltis, USA Inc.$175
  • Myovant Sciences Inc.$145
  • Evofem Biosciences, Inc.$141
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,307 in reported general payments places this provider in the 90th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

See all obstetrics & gynecology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$9,924
Medicare patients
43
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol11$540
Norgestimate-Ethinyl Estradiol13$149
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet11$83

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Willow Grove

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →